

**Clinical trial results:****A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine with or without Metformin****Summary**

EudraCT number	2014-003502-33
Trial protocol	SK HU
Global end of trial date	29 August 2016

Results information

Result version number	v2 (current)
This version publication date	02 January 2019
First version publication date	03 September 2017
Version creation reason	

Trial information**Trial identification**

Sponsor protocol code	D5553C00002
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02229383
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	Pepparedsleden 1, Mölndal, Sweden, SE-431 83
Public contact	Global Clinical Leader, AstraZeneca, 011 +1 302 885 1180, ClinicalTrialTransparency@astrazeneca.com
Scientific contact	Global Clinical Leader, AstraZeneca, 011 +1 302 885 1180, ClinicalTrialTransparency@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 August 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 August 2016
Global end of trial reached?	Yes
Global end of trial date	29 August 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the change from baseline in hemoglobin A1c (HbA1c) achieved with exenatide once weekly (EQW) added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.

Protection of trial subjects:

This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonisation/Good Clinical Practice and applicable regulatory requirements and the AstraZeneca policy on Bioethics.

Background therapy:

Insulin glargine titrated to achieve a target glucose of 4.0 to 5.5 millimoles per liter [72 to 99 milligram per deciliter (mg/dL)]; metformin as prescribed by the Investigator.

Evidence for comparator: -

Actual start date of recruitment	06 September 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Hungary: 59
Country: Number of subjects enrolled	Poland: 47
Country: Number of subjects enrolled	Romania: 45
Country: Number of subjects enrolled	Slovakia: 38
Country: Number of subjects enrolled	United States: 250
Country: Number of subjects enrolled	South Africa: 22
Worldwide total number of subjects	461
EEA total number of subjects	189

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	353
From 65 to 84 years	108
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted in 107 centers globally between 06 September 2014 and 29 August 2016.

Pre-assignment

Screening details:

The study had a Screening Visit, an 8-week insulin dose optimization phase, followed by a 28-week randomized, double-blind treatment phase. A total of 464 participants were randomized and entered the double-blind Treatment Period. Of which, 3 participants from 1 center in the United States have been excluded from analyses.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Exenatide

Arm description:

Exenatide 2 milligram (mg) 1 time per week + titrated basal insulin glargine with or without metformin.

Arm type	Experimental
Investigational medicinal product name	Exenatide
Investigational medicinal product code	
Other name	Bydureon
Pharmaceutical forms	Powder for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

2 mg one time per week, injection

Arm title	Placebo
------------------	---------

Arm description:

Placebo (matching with exenatide) 1 time per week + titrated basal insulin glargine with or without metformin.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Matching with exenatide one time per week, injection

Number of subjects in period 1	Exenatide	Placebo
Started	232	229
Received treatment	231	229
Safety analysis set	231	229
Intent-to-treat (ITT) analysis set	230	228
Completed	212	207
Not completed	20	22
Adverse event, serious fatal	-	1
Consent withdrawn by subject	4	6
Adverse event, non-fatal	7	4
Unspecified	3	8
Lost to follow-up	5	3
Did not receive treatment	1	-

Baseline characteristics

Reporting groups

Reporting group title	Exenatide
Reporting group description: Exenatide 2 milligram (mg) 1 time per week + titrated basal insulin glargine with or without metformin.	
Reporting group title	Placebo
Reporting group description: Placebo (matching with exenatide) 1 time per week + titrated basal insulin glargine with or without metformin.	

Reporting group values	Exenatide	Placebo	Total
Number of subjects	232	229	461
Age categorical			
Units: Subjects			
In Utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	182	171	353
From 65-84 years	50	58	108
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	57.8	57.6	-
standard deviation	± 9.01	± 10.28	-
Gender, Male/Female			
Units: Subjects			
Female	119	122	241
Male	113	107	220
Race, Customized			
Units: Subjects			
American Indian Or Alaska Native	1	0	1
Asian	4	2	6
Black Or African American	19	28	47
Native Hawaiian Or Other Pacific Islander	1	0	1
Other	1	4	5
White	206	195	401

End points

End points reporting groups

Reporting group title	Exenatide
Reporting group description:	Exenatide 2 milligram (mg) 1 time per week + titrated basal insulin glargine with or without metformin.
Reporting group title	Placebo
Reporting group description:	Placebo (matching with exenatide) 1 time per week + titrated basal insulin glargine with or without metformin.

Primary: Change in HbA1c From Baseline to Week 28

End point title	Change in HbA1c From Baseline to Week 28
End point description:	To compare the change from baseline in HbA1c achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment. Only participants with data available for analysis are presented.
End point type	Primary
End point timeframe:	Baseline to Week 28

End point values	Exenatide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	205	206		
Units: Percentage of HbA1c				
least squares mean (confidence interval 95%)	-0.96 (-1.12 to -0.81)	-0.22 (-0.38 to -0.07)		

Statistical analyses

Statistical analysis title	Change in HbA1c - baseline to Week 28
Statistical analysis description:	To compare the change from baseline in HbA1c achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.
Comparison groups	Exenatide v Placebo
Number of subjects included in analysis	411
Analysis specification	Pre-specified
Analysis type	superiority ^[1]
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-0.74

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.94
upper limit	-0.54
Variability estimate	Standard error of the mean
Dispersion value	0.101

Notes:

[1] - Treatment, region, baseline HbA1c (< or ≥ 9.0%), baseline sulphonylurea (SU)-use, week, treatment by week interaction as fixed factors; baseline value as covariate.

Secondary: Change in Body Weight From Baseline to Week 28

End point title	Change in Body Weight From Baseline to Week 28
-----------------	--

End point description:

To compare the change from baseline in body weight achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment. Only participants with data available for analysis are presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 28

End point values	Exenatide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	205	208		
Units: Kilogram				
least squares mean (confidence interval 95%)	-1.04 (-1.54 to -0.53)	0.48 (-0.02 to 0.98)		

Statistical analyses

Statistical analysis title	Change in body weight - baseline to Week 28
----------------------------	---

Statistical analysis description:

To compare the change from baseline in body weight achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.

Comparison groups	Exenatide v Placebo
Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority ^[2]
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-1.52

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.19
upper limit	-0.85
Variability estimate	Standard error of the mean
Dispersion value	0.341

Notes:

[2] - Treatment, region, baseline HbA1c (< or ≥ 9.0%), baseline SU-use, week, treatment by week interaction as fixed factors; baseline value as covariate.

Secondary: Change From Baseline to Week 28 in 2-hour Postprandial Glucose (PPG) After a Standard Meal Tolerance Test (MTT)

End point title	Change From Baseline to Week 28 in 2-hour Postprandial Glucose (PPG) After a Standard Meal Tolerance Test (MTT)
-----------------	---

End point description:

To compare the change from baseline in 2-hour PPG after a standard MTT achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment. Only participants with data available for analysis are presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 28

End point values	Exenatide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	200	204		
Units: mg/dL				
least squares mean (confidence interval 95%)	-28.73 (-40.0 to -17.45)	-0.96 (-12.41 to 10.48)		

Statistical analyses

Statistical analysis title	Change in 2 hr PPG - baseline to Week 28
----------------------------	--

Statistical analysis description:

To compare the change from baseline in 2-hour PPG after a standard MTT achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.

Comparison groups	Exenatide v Placebo
Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority ^[3]
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (final values)
Point estimate	-27.76

Confidence interval	
level	95 %
sides	2-sided
lower limit	-39.07
upper limit	-16.45
Variability estimate	Standard error of the mean
Dispersion value	5.754

Notes:

[3] - Treatment, region, baseline HbA1c (< or ≥ 9.0%), baseline SU-use (yes vs. no) as fixed factors; baseline value as covariate.

Secondary: Percentage of Participants Achieving HbA1c <7.0% at Week 28

End point title	Percentage of Participants Achieving HbA1c <7.0% at Week 28
End point description:	
To compare the percentage of participants achieving HbA1c <7.0% between EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment.	
End point type	Secondary
End point timeframe:	
Baseline to Week 28	

End point values	Exenatide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	230	228		
Units: Percentage of participants				
number (confidence interval 95%)	32.6 (26.6 to 38.7)	7.0 (3.7 to 10.3)		

Statistical analyses

Statistical analysis title	Percentage of participants achieving HbA1c <7%
Statistical analysis description:	
To compare the percentage of participants achieving HbA1c <7.0% between EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.	
Comparison groups	Exenatide v Placebo
Number of subjects included in analysis	458
Analysis specification	Pre-specified
Analysis type	superiority ^[4]
P-value	< 0.001 ^[5]
Method	Cochran-Mantel-Haenszel

Notes:

[4] - Stratified by baseline HbA1c (<9.0% or ≥9.0%) and baseline SU-use (yes vs. no).

[5] - Difference in percentages = 25.6

Secondary: Change From Baseline to Week 28 in Daily Insulin Dose

End point title	Change From Baseline to Week 28 in Daily Insulin Dose
-----------------	---

End point description:

To compare the change from baseline in daily insulin dose achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment. Only participants with data available for analysis are presented.

End point type	Secondary
End point timeframe:	
Baseline to Week 28	

End point values	Exenatide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	209	208		
Units: Units				
least squares mean (confidence interval 95%)	1.6 (0.1 to 3.1)	3.5 (2.0 to 5.1)		

Statistical analyses

Statistical analysis title	Change in daily insulin dose - baseline to Week 28
-----------------------------------	--

Statistical analysis description:

To compare the change from baseline in daily insulin dose achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.

Comparison groups	Exenatide v Placebo
Number of subjects included in analysis	417
Analysis specification	Pre-specified
Analysis type	superiority ^[6]
P-value	= 0.074
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	1.08

Notes:

[6] - Treatment, region, baseline HbA1c (< or ≥ 9.0%), baseline SU-use, week, treatment by week interaction as fixed factors; baseline value as covariate.

Secondary: Percentage of Participants Achieving HbA1c <7.0% at Week 28, No Weight Gain at Week 28, and No Major Hypoglycemia Over 28 Weeks

End point title	Percentage of Participants Achieving HbA1c <7.0% at Week 28, No Weight Gain at Week 28, and No Major Hypoglycemia Over 28 Weeks
-----------------	---

End point description:

To compare the percentage of participants achieving HbA1c <7.0% at Week 28, no weight gain at Week 28, and no major hypoglycemia over 28 weeks between EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin. The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 28

End point values	Exenatide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	230	228		
Units: Percentage of participants				
number (confidence interval 95%)	22.2 (16.8 to 27.5)	2.2 (0.3 to 4.1)		

Statistical analyses

Statistical analysis title	HbA1c <7.0%, no weight gain or hypoglycemia
----------------------------	---

Statistical analysis description:

To compare the percentage of participants achieving HbA1c <7.0% at Week 28, no weight gain at Week 28, and no major hypoglycemia over 28 weeks between EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin.

Comparison groups	Exenatide v Placebo
-------------------	---------------------

Number of subjects included in analysis	458
---	-----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	superiority ^[7]
---------------	----------------------------

P-value	< 0.001 ^[8]
---------	------------------------

Method	Cochran-Mantel-Haenszel
--------	-------------------------

Notes:

[7] - Stratified by baseline HbA1c (<9.0% or ≥9.0%) and baseline SU-use (yes vs. no).

[8] - Difference in percentages = 20.0

Secondary: Change in Seated Systolic Blood Pressure (SBP) From Baseline to Week 28

End point title	Change in Seated Systolic Blood Pressure (SBP) From Baseline to Week 28
-----------------	---

End point description:

To compare the change from baseline in seated SBP achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment. Only participants with data available for analysis are presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 28

End point values	Exenatide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	208	210		
Units: millimeter of mercury				
least squares mean (confidence interval 95%)	-2.5 (-4.4 to -0.7)	-0.7 (-2.6 to 1.1)		

Statistical analyses

Statistical analysis title	Change in SBP - baseline to Week 28
-----------------------------------	-------------------------------------

Statistical analysis description:

To compare the change from baseline in seated SBP achieved with EQW added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment.

Comparison groups	Exenatide v Placebo
Number of subjects included in analysis	418
Analysis specification	Pre-specified
Analysis type	superiority ^[9]
P-value	= 0.11
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	1.13

Notes:

[9] - Treatment, region, baseline HbA1c (< or ≥ 9.0%), baseline SU-use, week, treatment by week interaction as fixed factors; baseline value as covariate.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From Baseline (Day 1) up to Week 28

Adverse event reporting additional description:

Safety analysis set included all participants who received at least 1 dose of randomized study medication. Total number of Deaths is reported for the overall study period, including the off-treatment period; Serious and Non-serious adverse event data is reported for the on-treatment period.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo (matching with exenatide) 1 time per week + titrated basal insulin glargine with or without metformin.

Reporting group title	Exenatide
-----------------------	-----------

Reporting group description:

Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin.

Serious adverse events	Placebo	Exenatide	
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 229 (4.80%)	11 / 231 (4.76%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Humerus fracture			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			

subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Angina unstable			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	2 / 229 (0.87%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	1 / 229 (0.44%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Carpal tunnel syndrome			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			

subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal mass			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Acute stress disorder			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			

subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck obstruction			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Musculoskeletal chest pain			
subjects affected / exposed	2 / 229 (0.87%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 229 (0.44%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Osteomyelitis			
subjects affected / exposed	0 / 229 (0.00%)	1 / 231 (0.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 229 (0.44%)	0 / 231 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Exenatide	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	36 / 229 (15.72%)	40 / 231 (17.32%)	
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	13 / 229 (5.68%)	5 / 231 (2.16%)	
occurrences (all)	15	6	
General disorders and administration site conditions			
Injection site nodule			
subjects affected / exposed	1 / 229 (0.44%)	12 / 231 (5.19%)	
occurrences (all)	1	14	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	9 / 229 (3.93%)	12 / 231 (5.19%)	
occurrences (all)	10	13	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	15 / 229 (6.55%)	18 / 231 (7.79%)	
occurrences (all)	21	25	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
03 October 2014	<p>Outcome measure of secondary objective was modified to specify "major" hypoglycemia. Insulin glargine, metformin, and rescue therapy would be sourced locally. Exclusion criterion #25 was included as inclusion criterion #9. Cut off for serum calcitonin concentration was decreased to 40 picogram per milliliter. Tobacco, caffeine, and strenuous exercise were added to list of restrictions 24 hours prior to each visit. Discontinuation procedures were amended to include a review when Investigator deemed it necessary to temporarily stop and re-start study medication. Discontinued participants were required to complete Follow-up visit (Visit 15), and who had symptoms of hypoglycemia were to record glucose measurements and episode details in participant diary. Study Plan updated to clarify when study diary was given out, procedures for collecting study diary, when study medication was dispensed and used/unused medication was collected. Text added to differentiate procedures for Early Termination and Rescue Visits, to indicate IVRS should be called on day of consent, to clarify that participants undergoing rescue therapy were to perform 6 point self-monitored blood glucose profile before returning for Rescue Visit, to indicate that staff monitored study medication administration at study visits, and to indicate when MTTs should be performed. Text regarding MTT updated to include instruction on MTT timing and for how MTT should have been performed. Blood pressure measurement instructions were modified. Investigators should contact medical monitor if a participant developed a liver function test abnormality. Hy's Law text updated to state that cases meeting any of identification criteria required an unscheduled laboratory draw. Hypoglycemia assessment updated with criteria for classification. Sponsor should have been contacted regarding hypoglycemia events. Added use of SU as a stratification factor for exploratory analyses. Clarified assessment of causality for adverse events.</p>
20 February 2015	<p>The proportion of participants rescued or discontinued for lack of glycemic control at Week 28 was added as an exploratory outcome measure. Inclusion criterion #7 was clarified to state that participants may only take basal insulin glargine once daily. Exclusion criterion #32 was amended to include participation in an interventional clinical trial and to clarify that only administration of an investigational drug would have rendered a participant as ineligible. The Study Plan and Timing of Procedures was updated. This update clarified study visit windows, when used/unused study medication was to be collected, when training for study drug administration was to be received by the participant, and visits when rescue medication could have been dispensed. Review of potential cardiovascular (CV) event triggers was added to all visits where adverse events and concomitant medication were reviewed. Text was added to indicate that metformin should be taken with the next meal, and does not need to be taken at the study center, and that urine should be collected right before time 0 of the MTT. Text was added to indicate that study medication may be dispensed at a Rescue Visit. Text was added to clarify that potential CV event triggers would be reviewed at specified study visits. Text was added to indicate that urine was collected right before time 0 of the MTT. Text was amended to indicate that antibody results would be presented in the CSR. Text was added to clarify that the baseline physical examination data are collection at Visit 1. Text was added to clarify that there is no restriction on fathering children during the study. Text was added to describe the adjudication of CV events.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Please note that the data from 4 subjects enrolled at one site were omitted due to potential scientific misconduct at that site. Study conclusions remain unchanged.

Notes: